Elekta AB (publ) (EKTA B.ST) Stock Price
Elekta AB (publ) Price
Revenue has compounded at 7.1% per year over the past 19 years to 16.72 B SEK. Earnings per share have declined at 2.1% per year over the last 18 years. Elekta AB (publ)'s net margin stands at -3.1%, down from 7.9% several years earlier. Elekta AB (publ) currently offers a dividend yield of about 4.36%. The payout ratio is around 185% of earnings. The dividend has grown at 12.6% per year over the past 19 years. Analysts set a median price target of 54.06 SEK, implying 1.9% below the current price. Of 21 analysts, 5 rate the stock a buy — an overall Sell consensus.
Elekta AB (publ) stock price
Elekta AB (publ) business model & stock analysis
Frequently asked questions about Elekta AB (publ)
Elekta AB (publ) is a global medical technology company that specializes in developing and marketing innovative solutions for cancer and brain disorders. The company's business model revolves around providing advanced radiotherapy, stereotactic radiosurgery, and precision radiation medicine systems and software to healthcare providers worldwide. Elekta AB (publ) operates through two primary segments: Radiation Therapy and Magnetic Resonance Imaging (MRI). By offering cutting-edge equipment, software, and clinical management for precise treatment planning and delivery, Elekta AB (publ) aims to improve patient outcomes and enhance the overall efficiency of cancer care. This commitment to technological advancements and medical excellence positions Elekta AB (publ) as a leader in the field of radiation therapy.
Elekta AB (publ) is primarily active in the medical technology industry.
The main competitors of Elekta AB (publ) in the market include Varian Medical Systems, Accuray Incorporated, and Siemens Healthineers.
Elekta AB (publ) is a renowned company with a rich history and background. Established in 1972, Elekta specializes in developing advanced technology and comprehensive treatment solutions for cancer and brain disorders. Headquartered in Stockholm, Sweden, the company has expanded globally, with a presence in more than 100 countries. Elekta's innovation in radiation therapy, radiosurgery, and brachytherapy has revolutionized medical procedures, improving patient outcomes worldwide. With a commitment to precision and innovation, Elekta continues to collaborate with leading experts in healthcare, offering state-of-the-art solutions to enhance the quality of patient care and contribute to life-saving advancements in the field of oncology and neurosurgery. Overall, Elekta AB (publ) is a leading force in the medical technology sector, dedicated to transforming cancer care and neurological treatments.
Elekta AB (publ) has achieved several significant milestones in its trajectory. Over the years, the company has pioneered innovative solutions in the field of radiation therapy and precise neurosurgery. Elekta AB (publ) introduced the revolutionary Elekta Synergy, a state-of-the-art radiation treatment system that enables accurate targeting of tumors while minimizing damage to surrounding healthy tissues. Furthermore, the company developed the Leksell Gamma Knife, a non-invasive radiosurgery system for treating brain disorders with exceptional precision. Elekta AB (publ) continues to expand its global presence and collaborate with leading healthcare institutions, solidifying its position as a trusted provider of advanced medical technology solutions.
Elekta AB (publ) is primarily present in various countries and regions around the world. The company has a global presence, with a strong focus in North America, Europe, and Asia Pacific. Elekta AB (publ) operates in numerous countries, including the United States, Sweden (where it is headquartered), Germany, the United Kingdom, France, China, Australia, and many others. With its innovative medical technology solutions, Elekta AB (publ) continues to expand its presence and serve customers in the healthcare industry across diverse regions, making a significant impact in the field of radiation therapy and neurosurgery.
Elekta AB (publ) represents a company philosophy centered around innovation, quality, and patient care. With a dedicated focus on advancing cancer treatment and improving patient outcomes, Elekta AB (publ) strives to provide state-of-the-art technology and solutions in radiation therapy and radiosurgery. They are committed to developing cutting-edge medical devices and software systems that enable precise and personalized cancer treatment options. Elekta AB (publ) values collaboration, integrity, and a customer-centric approach, ensuring that patients and healthcare professionals have access to the best possible treatment solutions. With a strong global presence, Elekta AB (publ) continues to drive advancements in cancer care worldwide.
Analysts currently set an average price target of 56.90 SEK for the Elekta AB (publ) stock (median: 54.06 SEK), implying +3.3 % versus the latest price. The consensus is based on 21 analyst ratings.
21 analysts currently rate the Elekta AB (publ) stock: 5 recommend buying, 7 holding and 9 selling.
Converted at the current exchange rate, the Elekta AB (publ) share trades at 4.94 EUR (55.10 SEK).
The Elekta AB (publ) share (EKTA B.ST) is listed on 8 stock exchanges, including: London (0O5H.L), Frankfurt (EJXB.F), München (EJXB.MU), Düsseldorf (EJXB.DU), Stockholm (EKTA B.ST).
Elekta AB (publ) is a globally leading company in the development and production of clinical systems for cancer treatment and neurological disorders. The company was founded in 1972 in Stockholm, Sweden, and has been listed on the Stockholm Stock Exchange since 1994. The core business of Elekta includes the planning and delivery of devices and software used in the treatment of cancer and neurological disorders. Elekta offers a variety of products and solutions tailored to the needs of clinics and hospitals worldwide. One of Elekta's main business areas is radiation therapy. The company offers innovative devices such as Elekta's linear accelerators, which generate high-speed particles to target the tumor. Elekta has also developed advanced imaging technology to assist doctors in diagnosis and determining the appropriate treatment method. Another important business area for Elekta is neurological therapy. Here, Elekta has developed devices for accurate diagnosis and treatment of brain tumors, Parkinson's disease, and epilepsy, among others. The offering is complemented by a wide range of software solutions that facilitate treatment planning and monitoring. Elekta works closely with doctors and research institutions to develop innovative solutions that help patients improve their health. Elekta has directed its research and development capacities towards creating new technologies that will further improve cancer treatment in the future. An example is the advanced "Unity" technology, which enables accuracy 30 times higher than conventional radiation. Elekta also has a wide network of service centers to ensure customer support. These facilities provide customers with the solutions they need to facilitate their work and improve patient care. Elekta's business model focuses on the needs of hospitals and clinics worldwide. With its offering of innovative devices and software solutions, Elekta emphasizes quality and technical excellence to meet the needs of customers and patients. The company has gained a global reputation for innovation and outstanding products and is known in the industry for its customer orientation. Overall, Elekta is a leading provider of clinical systems for cancer treatment and neurological disorders. With the continuous development of innovative technologies and products, as well as a strong network of service centers, Elekta is well positioned to consolidate its position in the global health market.
The revenue of Elekta AB (publ) is 16.72 B SEK. This figure is based on current financial data and reflects the company's business performance.
The profit of Elekta AB (publ) is -520.00 M SEK. The net profit reflects the company's profitability after deducting all expenses.
The price-to-earnings ratio (P/E) of Elekta AB (publ) is currently -40.49. The P/E ratio compares the current share price to the earnings per share and helps investors assess the valuation of the Elekta AB (publ) stock.
The price-to-sales ratio (P/S) of Elekta AB (publ) is currently 1.26. The P/S ratio compares the market capitalization to the annual revenue and serves as a valuation metric for the Elekta AB (publ) stock.
The Eulerpool Quality Score for Elekta AB (publ) is 0/10.
The ISIN of Elekta AB (publ) is SE0000163628. The ISIN (International Securities Identification Number) is a globally unique identifier for securities.
The WKN of Elekta AB (publ) is 896279. The WKN (Wertpapierkennnummer) is a six-digit German security identification number.
The ticker of Elekta AB (publ) is EKTA B.ST. The ticker symbol is used to trade Elekta AB (publ) shares on the stock exchange.
Elekta AB (publ) stock
Elekta AB (publ) Peer Group
Elekta AB (publ) Ticker
Elekta AB (publ) FIGI
All fundamentals and in-depth analysis of Elekta AB (publ)
Our stock analysis for Elekta AB (publ) stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Elekta AB (publ). If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.